6505--Metformin IR Tablets - REPACK PROGRAM

The Department of Veterans Affairs National Acquisition Center is soliciting proposals for Metformin HCL IR (immediate release) tablets through Solicitation 36E79725R0013. The procurement is divided into two distinct groups: Group 1 for Other Government Agencies (OGAs) including DoD, Indian Health Service, and Bureau of Prisons, and Group 2 specifically for VA facilities. Offerors must provide tablets in multiple strengths (500mg, 850mg, and 1000mg) and package sizes, with requirements including FDA compliance, current Good Manufacturing Practices (cGMP) certification, unique NDC numbers, and Drug Supply Chain Security Act (DSCSA) compliance. Proposals are due by February 13, 2025, at 2:30 PM CST, with the government potentially awarding separate contracts for each group or a single contract covering both. Evaluation criteria will likely focus on meeting technical specifications, regulatory compliance, pricing, and distribution capabilities.

The solicitation is not designated as a set-aside contract, making it open to all qualified pharmaceutical manufacturers. The contract structure includes a base year with four one-year option periods, allowing for potential long-term engagement. Distribution will occur through VA's Pharmaceutical Prime Vendor program for Group 1 and the VA Pharmaceutical Repackaging Program for Group 2, with delivery requirements including minimum package sizes of 1,000 tablets during the base year and 10,000 tablet drums for option years. A mandatory 0.5% Cost Recovery Fee must be included in pricing. The contract will serve multiple federal entities including VA facilities, Department of Defense, Indian Health Service, Bureau of Prisons, Federal Health Care Center, and Option 2 State Veterans Homes. While specific award values are not disclosed, the broad scope and multi-year nature suggest a potentially significant procurement opportunity for pharmaceutical manufacturers specializing in Metformin IR tablets.